March 26, 2018 / 11:20 AM / 6 months ago

BRIEF-Flex Pharma Reports Positive Topline Data From Exploratory Phase 2 Trial Of FLX-787 In Multiple Sclerosis

March 26 (Reuters) - Flex Pharma Inc:

* FLEX PHARMA REPORTS POSITIVE TOPLINE DATA FROM EXPLORATORY PHASE 2 TRIAL OF FLX-787 IN MULTIPLE SCLEROSIS

* FLEX PHARMA - FLX-787 REDUCED CRAMP/SPASM FREQUENCY AND INCREASED CRAMP-FREE DAYS IN MS PATIENTS IN PRE-SPECIFIED ANALYSIS OF PARALLEL TREATMENT PHASE

* FLEX PHARMA INC - FLX-787 WAS GENERALLY WELL TOLERATED WITH NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS REPORTED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below